Frederique BERGER

Mrs. Frederique BERGER

Institut Curie, France
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
FBFrancois-Clement Bidard
Francois-Clement Bidard
WJWilliam Jacot
William Jacot
NKNicolas Kiavue
Nicolas Kiavue
SDSylvain Dureau
Sylvain Dureau
AKAmir Kadi
Amir Kadi
JPJean-Yves Pierga
Jean-Yves Pierga
About two-thirds of newly diagnosed metastatic breast cancers (MBCs) display a hormone receptor–positive, ERBB2 (also known as HER2)-negative phenotype.1 In addition to being the principal component of breast cancer biology and genomic landscapes,2,3 hormone receptor status was first characterized as a strong predictive factor of response to endocrine therapy.4 In the context of hormone receptor–positive MBC, a key question therefore became whether endocrine therapy or chemotherapy, when administered as first-line therapy, would be the most beneficial treatment in terms of survival and quality of life. In 2003, a meta-analysis5 of published data aggregated 692 patients from 6 trials conducted between 1963 and 1995; compared with up-front endocrine therapy, first-line chemotherapy yielded higher toxicity and response rates but no longer overall survival (OS). Because of the palliative context of MBC, endocrine therapy has been then established as the preferred first-line treatment of hormone receptor–positive, ERBB2-negative MBC by all expert consensus.6-8 Experts, however, acknowledge exceptions to the systematic use of endocrine therapy as up-front therapy: patients with a rapidly evolving disease, clinically meaningful symptoms, impaired general condition, and/or life-threatening disease, commonly referred to as visceral crisis.9 Until recently, real-life studies repeatedly reported that chemotherapy is administered as first-line therapy in 15% to 50% of patients with hormone receptor–positive, ERBB2-negative MBC.10-15

21 December 2010 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
ACArmelle Corpet
Armelle Corpet
LKLeanne De Koning
Leanne De Koning
JTJoern Toedling
Joern Toedling
ASAlexia Savignoni
Alexia Savignoni
FBFrederique BERGER
Frederique BERGER
GAGeneviève Almouzni
Geneviève Almouzni
Mammalian cells possess two isoforms of the histone H3–H4 chaperone anti‐silencing function 1 (Asf1), Asf1a and Asf1b. However to date, whether they have individual physiological roles has remained elusive. Here, we aim to elucidate the functional importance of Asf1 isoforms concerning both basic and applied aspects. First, we reveal a specific proliferation‐dependent expression of human Asf1b unparalleled by Asf1a. Strikingly, in cultured cells, both mRNA and protein corresponding to Asf1b decrease upon cell cycle exit. Depletion of Asf1b severely compromises proliferation, leads to aberrant nuclear structures and a distinct transcriptional signature. Second, a major physiological implication is found in the applied context of tissue samples derived from early stage breast tumours in which we examined Asf1a/b levels. We reveal that overexpression of Asf1b mRNA correlate with clinical data and disease outcome. Together, our results highlight a distribution of tasks between the distinct Asf1 isoforms, which emphasizes a specialized function of Asf1b required for proliferation capacity. We discuss the implications of these results for breast cancer diagnosis and prognosis.

20 November 2014 in Molecular Oncology
Verified
Journal Article
Open access
RORocío Montes de Oca
Rocío Montes de Oca
ZGZachary A. Gurard-Levin
Zachary A. Gurard-Levin
FBFrederique BERGER
Frederique BERGER
HRHaniya Rehman
Haniya Rehman
EMElise Martel
Elise Martel
GAGenevieve Almouzni
Genevieve Almouzni
Background: Breast cancer is a heterogeneous disease with different molecular subtypes that have varying responses to therapy. An ongoing challenge in breast cancer research is to distinguish high‐risk patients from good prognosis patients. This is particularly difficult in the low‐grade, ER‐positive luminal A tumors, where robust diagnostic tools to aid clinical treatment decisions are lacking. Recent data implicating chromatin regulators in cancer initiation and progression offers a promising avenue to develop new tools to help guide clinical decisions.Methods: Here we exploit a published transcriptome dataset and an independent validation cohort to correlate the mRNA expression of selected chromatin regulators with respect to the four intrinsic breast cancer molecular subtypes. We then perform univariate and multivariate analyses to compare the prognostic value of a panel of chromatin regulators to Ki67, a currently utilized proliferation marker.Results: Unsupervised hierarchical clustering revealed a gene cluster containing several histone chaperones and histone variants highly‐expressed in the proliferative subtypes (basal‐like, HER2‐positive, luminal B) but not in the luminal A subtype. Several chromatin regulators, including the histone chaperones CAF‐1 (subunits p150 and p60), ASF1b, and HJURP, and the centromeric histone variant CENP‐A, associated with local and metastatic relapse and poor patient outcome. Importantly, we find that HJURP can discriminate favorable and unfavorable outcome within the luminal A subtype, outperforming the currently utilized proliferation marker Ki67, as an independent prognostic marker for luminal A patients.Conclusions: The integration of chromatin regulators as clinical biomarkers, in particular the histone chaperone HJURP, will help guide patient substratification and treatment options for low‐risk luminal A breast carcinoma patients.

9 September 2021 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
ASAmanda Bortolini Silveira
Amanda Bortolini Silveira
FBFrançois-Clément Bidard
François-Clément Bidard
MTMarie-Laure Tanguy
Marie-Laure Tanguy
EGElodie Girard
Elodie Girard
OTOlivier Trédan
Olivier Trédan
JPJean-Yves Pierga
Jean-Yves Pierga
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are two cancer-derived blood biomarkers that inform on patient prognosis and treatment efficacy in breast cancer. We prospectively evaluated the clinical validity of quantifying both CTCs (CellSearch) and ctDNA (targeted next-generation sequencing). Their combined value as prognostic and early monitoring markers was assessed in 198 HER2-negative metastatic breast cancer patients. All patients were included in the prospective multicenter UCBG study COMET (NCT01745757) and treated by first-line chemotherapy with weekly paclitaxel and bevacizumab. Blood samples were obtained at baseline and before the second cycle of chemotherapy. At baseline, CTCs and ctDNA were respectively detected in 72 and 74% of patients and were moderately correlated (Kendall’s τ = 0.3). Only 26 (13%) patients had neither detectable ctDNA nor CTCs. Variants were most frequently observed in TP53 and PIK3CA genes. KMT2C/MLL3 variants detected in ctDNA were significantly associated with a lower CTC count, while the opposite trend was seen with GATA3 alterations. Both CTC and ctDNA levels at baseline and after four weeks of treatment were correlated with survival. For progression-free and overall survival, the best multivariate prognostic model included tumor subtype (triple negative vs other), grade (grade 3 vs other), ctDNA variant allele frequency (VAF) at baseline (per 10% increase), and CTC count at four weeks (≥5CTC/7.5 mL). Overall, this study demonstrates that CTCs and ctDNA have nonoverlapping detection profiles and complementary prognostic values in metastatic breast cancer patients. A comprehensive liquid-biopsy approach may involve simultaneous detection of ctDNA and CTCs.

1 July 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
David GROHEUXDavid GROHEUX
David GROHEUX
EHElif Hindié
Elif Hindié
SGSylvie Giacchetti
Sylvie Giacchetti
AHAnne Sophie Hamy
Anne Sophie Hamy
FBFrederique BERGER
Frederique BERGER
MEMarc Espié
Marc Espié

14 November 2019 in Breast Cancer Research
Verified
Journal Article
Open access
WJWilliam Jacot
William Jacot
PCPaul Cottu
Paul Cottu
FBFrederique BERGER
Frederique BERGER
CDCoraline Dubot
Coraline Dubot
LVLaurence Venat-Bouvet
Laurence Venat-Bouvet
FBFrancois-Clement Bidard
Francois-Clement Bidard
Background: In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC.Methods: Main inclusion criteria for screening were as follows: women with HER2-negative MBC treated with ≥ 2 prior lines of chemotherapy and measurable disease. CTC with aHER2/CEP17 ratio of ≥ 2.2 by fluorescent in situ hybridization (CellSearch) were considered to beHER2-amplified (HER2amp). Patients with ≥ 1HER2ampCTC were eligible for the treatment phase (T-DM1 monotherapy). The primary endpoint was the overall response rate.Results: In 154 screened patients, ≥ 1 and ≥ 5 CTC/7.5 ml of blood were detected inN = 118 (78.7%) andN = 86 (57.3%) patients, respectively. ≥1HER2ampCTC was found in 14 patients (9.1% of patients with ≥ 1 CTC/7.5 ml). Among 11 patients treated with T-DM1, one achieved a confirmed partial response. Four patients had a stable disease as best response. Median PFS was 4.8 months while median OS was 9.5 months.Conclusions: CTC withHER2amplification can be detected in a limited subset of HER2-negative MBC patients. Treatment with T-DM1 achieved a partial response in only one patient.Trial registration: NCT01975142, Registered 03 November 2013